Tarsus Pharmaceuticals, Inc. (TARS)
80.28
+3.39
(+4.41%)
USD |
NASDAQ |
Nov 13, 16:00
80.40
+0.12
(+0.15%)
After-Hours: 19:59
Tarsus Pharmaceuticals Enterprise Value : 3.737B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 3.737B |
| November 12, 2026 | 3.570B |
| November 11, 2026 | 3.564B |
| November 10, 2026 | 3.419B |
| November 09, 2026 | 3.272B |
| November 06, 2026 | 3.161B |
| November 05, 2026 | 3.108B |
| November 04, 2026 | 3.184B |
| November 03, 2026 | 3.360B |
| November 02, 2026 | 3.394B |
| October 30, 2026 | 3.469B |
| October 29, 2026 | 3.437B |
| October 28, 2026 | 3.331B |
| October 27, 2026 | 3.268B |
| October 26, 2026 | 3.232B |
| October 23, 2026 | 3.142B |
| October 22, 2026 | 3.333B |
| October 21, 2026 | 3.255B |
| October 20, 2026 | 3.281B |
| October 19, 2026 | 3.206B |
| October 16, 2026 | 3.135B |
| October 15, 2026 | 3.279B |
| October 14, 2026 | 3.343B |
| October 13, 2026 | 3.271B |
| October 12, 2026 | 3.447B |
| Date | Value |
|---|---|
| October 09, 2026 | 3.386B |
| October 08, 2026 | 3.340B |
| October 07, 2026 | 3.408B |
| October 06, 2026 | 3.433B |
| October 05, 2026 | 3.450B |
| October 02, 2026 | 3.378B |
| October 01, 2026 | 3.499B |
| September 30, 2026 | 3.655B |
| September 29, 2026 | 2.957B |
| September 28, 2026 | 2.963B |
| September 25, 2026 | 2.914B |
| September 24, 2026 | 2.926B |
| September 23, 2026 | 2.854B |
| September 22, 2026 | 2.974B |
| September 21, 2026 | 2.991B |
| September 18, 2026 | 3.018B |
| September 17, 2026 | 3.059B |
| September 16, 2026 | 2.999B |
| September 15, 2026 | 3.024B |
| September 14, 2026 | 3.099B |
| September 11, 2026 | 3.071B |
| September 10, 2026 | 3.149B |
| September 09, 2026 | 3.221B |
| September 08, 2026 | 3.413B |
| September 04, 2026 | 3.567B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 161.88B |
| Amneal Pharmaceuticals, Inc. | 10.67B |
| Harmony Biosciences Holdings, Inc. | 1.444B |
| ANI Pharmaceuticals, Inc. | 1.807B |
| Corcept Therapeutics, Inc. | 7.615B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -668.33M |
| Revenue (Quarterly) | 194.57M |
| Total Expenses (Quarterly) | 862.90M |
| EPS Diluted (Quarterly) | -14.40 |
| Gross Profit Margin (Quarterly) | 92.86% |
| Profit Margin (Quarterly) | -343.5% |
| Earnings Yield | -18.91% |
| Normalized Earnings Yield | -7.068 |